Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.
Chad R HeatwoleElizabeth LuebbeSpencer RoseroKaty EichingerWilliam MartensJames HilbertJeanne DekdebrunNuran DilekChristine ZizziNicholas JohnsonAraya PuwanantRabi TawilGiovanni SchifittoChristopher A BeckJ Franklin RichesonWojciech ZarebaCharles ThorntonMichael P McDermottRichard MoxleyPublished in: Neurology (2020)
This study provides Class I evidence that for ambulatory patients with DM1, mexiletine does not significantly change 6-minute walk distance at 6 months.